Viewing Study NCT03298412


Ignite Creation Date: 2025-12-26 @ 10:20 PM
Ignite Modification Date: 2025-12-26 @ 10:20 PM
Study NCT ID: NCT03298412
Status: TERMINATED
Last Update Posted: 2020-09-11
First Post: 2017-09-12
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
Sponsor: Amgen
Organization: